Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with contralateral mediastinal or ipsilateral supraclavicular lymph node (N3) involvement.. The main question it aims
| Condition(s) | Non-small Cell Lung Cancer Stage III |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with contralateral mediastinal or ipsilateral supraclavicular lymph node (N3) involvement.. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, pat |
| Who can participate | Inclusion Criteria: 1. Age ≥ 18 years at time of signing the informed consent form (ICF). 2. Histologically or cytologically confirmed stage 3 B/C Non-Small Cell Lung Cancer (NSCLC) as assessed per the 8th American Joint Committee on Cancer (AJCC) with pathologically-confirmed contralateral mediastinal or ipsilateral supraclavicular (N3) lymph node involvement. 3. Primary tumor appropriate for resection with curative intent as assessed by the treating surgeon prior to study enrollment. 4. Absence of major associated pathologies and co-morbidities that elevate surgery risk to a prohibitive level, as assessed by treating surgeon prior to study enrollment. 5. Pulmonary function capacity capable of tolerating the lung resection proposed by the treating surgeon. 6. EGFR, ALK, wild-type assessed |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Georgetown University |
| Locations | Washington D.C., District of Columbia, United States; St Louis, Missouri, United States; Charlottesville, Virginia, United States |
| Start date | 2026-08 |
| NCT ID | NCT06449313 |
| Official listing | https://clinicaltrials.gov/study/NCT06449313 |